Soligenix moves forward with treatments for cutaneous t-cell lymphoma and psoriasis

Strategy supports global need and has potential use in growing home healthcare marketnew york, new york--(newsfile corp. - june 7, 2022) - pcg digital -- rising to the challenge in 2022, late-stage biopharma company soligenix (nasdaq: sngx) continues to move forward with developing and commercializing products to treat rare diseases where there is an unmet medical need. (rising to the challenges of rare disease treatment)
SNGX Ratings Summary
SNGX Quant Ranking